First Reported Case of Liver Damage Caused by Tirzepatide in a Patient with Metabolic Syndrome
A 37-year-old woman with metabolic syndrome developed elevated liver enzymes attributed to tirzepatide use, marking the first reported case of tirzepatide-induced hepatotoxicity despite the drug's known liver fat-reducing properties.
Quick Facts
What This Study Found
First reported case of tirzepatide-induced hepatotoxicity in a 37-year-old woman with metabolic syndrome, notable because tirzepatide typically reduces liver fat content.
Key Numbers
First reported case in the literature. Tirzepatide was recently FDA-approved for both type 2 diabetes and obesity.
How They Did This
Single case report documenting clinical presentation of elevated liver enzymes, diagnostic workup to exclude other causes, and attribution to tirzepatide use.
Why This Research Matters
As tirzepatide prescriptions rapidly increase for both diabetes and obesity, clinicians need to be aware that liver damage is a possible adverse effect — even though the drug generally improves liver metrics. Liver function monitoring should be part of routine care.
The Bigger Picture
Many metabolic drugs that generally benefit the liver can occasionally cause idiosyncratic liver injury. As tirzepatide joins the growing arsenal of GLP-1/GIP-based therapies, building a complete safety profile through pharmacovigilance is essential. This case contributes to that effort.
What This Study Doesn't Tell Us
Single case report — cannot determine incidence or risk factors. The mechanism of hepatotoxicity was not investigated. Other contributing factors to liver enzyme elevation may not have been fully excluded. The temporal relationship supports but does not prove causation.
Questions This Raises
- ?What is the mechanism of tirzepatide-induced hepatotoxicity — is it immunological or metabolic?
- ?Should routine liver function testing be recommended for all patients starting tirzepatide?
- ?Are patients with pre-existing metabolic syndrome at higher risk for this adverse effect?
Trust & Context
- Key Stat:
- First reported hepatotoxicity case Tirzepatide-induced liver enzyme elevation in a 37-year-old, paradoxically despite the drug's liver-protective reputation
- Evidence Grade:
- Preliminary evidence from a single case report. Establishes a safety signal for clinical awareness but cannot determine frequency or causation.
- Study Age:
- Published in 2024. Important early safety signal as tirzepatide prescriptions scale rapidly.
- Original Title:
- A Rare Case of Tirzepatide-Induced Hepatotoxicity.
- Published In:
- ACG case reports journal, 11(10), e01484 (2024)
- Authors:
- Sohal, Aalam(2), Casanova, Luis, Kowdley, Kris V
- Database ID:
- RPEP-09292
Evidence Hierarchy
Frequently Asked Questions
Doesn't tirzepatide usually help the liver?
Yes — studies have shown tirzepatide reduces liver fat content and is being investigated for fatty liver disease. However, as with many drugs that generally benefit an organ, rare cases of adverse effects can still occur. This paradox makes this case particularly noteworthy.
Should I worry about liver damage from tirzepatide?
This is a single case report — liver damage from tirzepatide appears to be very rare. However, it's reasonable to have baseline liver function tests before starting the medication and to report any symptoms like abdominal pain, dark urine, or yellowing of skin to your doctor.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09292APA
Sohal, Aalam; Casanova, Luis; Kowdley, Kris V. (2024). A Rare Case of Tirzepatide-Induced Hepatotoxicity.. ACG case reports journal, 11(10), e01484. https://doi.org/10.14309/crj.0000000000001484
MLA
Sohal, Aalam, et al. "A Rare Case of Tirzepatide-Induced Hepatotoxicity.." ACG case reports journal, 2024. https://doi.org/10.14309/crj.0000000000001484
RethinkPeptides
RethinkPeptides Research Database. "A Rare Case of Tirzepatide-Induced Hepatotoxicity." RPEP-09292. Retrieved from https://rethinkpeptides.com/research/sohal-2024-a-rare-case-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.